6-氯-3-三氟甲基-1H-吡唑并[3,4-D]嘧啶 | 1211590-25-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 6-氯-3-三氟甲基-1H-吡唑并[3,4-D]嘧啶
• 英文名称: 6-chloro-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine
• 英文别名: 6-chloro-3-(trifluoromethyl)-2H-pyrazolo[3,4-d]pyrimidine
• CAS: 1211590-25-8
• 化学式: C₆H₂ClF₃N₄
• 分子量: 222.557
• InChiKey: RCFCMWHDZCRZLY-UHFFFAOYSA-N

物化性质

• 密度：
  1.752±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  6-氯-3-三氟甲基-1H-吡唑并[3,4-D]嘧啶 在 对甲苯磺酸一水合物 、 palladium diacetate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 19.0h， 生成 2-(6'-bromo-1'-oxo-1'H-spiro[cyclopropane-1,4'-isoquinolin]-2'(3'H)-yl)-N-(1-(tetrahydro-2H-pyran-2-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)acetamide
  参考文献：
  名称：

  [FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS
  [EN] COMPOUNDS, COMPOSITIONS, AND METHODS

  摘要：

  The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.

  公开号：

  WO2023192390A1

文献信息

• [EN] DNA-DEPENDENT PROTEIN KINASE INHIBITOR<br/>[FR] INHIBITEUR DE PROTÉINE KINASE DÉPENDANTE DE L'ADN
  申请人：DIZAL JIANGSU PHARMACEUTICAL CO LTD

  公开号：WO2020238900A1

  公开（公告）日：2020-12-03

  Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as DNA-PK inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat DNA-PK related disorder (e.g., cancer).

  本文披露了式（I）的化合物及其药学上可接受的盐，这些化合物可用作DNA-PK抑制剂。还披露了包含一种或多种式（I）化合物的药物组合物，以及使用这些化合物或组合物来治疗DNA-PK相关疾病（例如癌症）的方法。
• WO2022/235699
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS<br/>[FR] COMPOSÉS PUISSANTS DE LIAISON À L'ASGPR PERMETTANT LA DÉGRADATION D'IMMUNOGLOBULINES ET D'AUTRES PROTÉINES
  申请人：[en]AVILAR THERAPEUTICS, INC.

  公开号：WO2022235699A2

  公开（公告）日：2022-11-10

  Extracellular protein degraders and compositions are provided that have a potent asialoglycoprotein receptor (ASGPR) Binding Ligand bound to an Extracellular Protein Targeting Ligand for the selective degradation of the Target Extracellular Protein, for example immunoglobulinin vivoto treat disorders mediated by the extracellular protein.
• [EN] LRRK2 INHIBITORS<br/>[FR] INHIBITEURS DE LRRK2
  申请人：[en]H. LUNDBECK A/S

  公开号：WO2023073013A1

  公开（公告）日：2023-05-04

  The present invention is directed to compounds of formula I. The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.
• [FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS<br/>[EN] COMPOUNDS, COMPOSITIONS, AND METHODS
  申请人：[en]DENALI THERAPEUTICS INC.

  公开号：WO2023192390A1

  公开（公告）日：2023-10-05

  The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.